Results 211 to 220 of about 41,565 (267)
Lancet, The, 2011 B lymphocytes are implicated in the pathogenesis of multiple sclerosis. We aimed to assess efficacy and safety of two dose regimens of the humanised anti-CD20 monoclonal antibody ocrelizumab in patients with relapsing-remitting multiple ...
Ludwig Kappos +2 more
exaly +2 more sources
Risk factors for relapse in relapsing remitting multiple sclerosis [PDF]
British Journal of Neuroscience Nursing, 2021 Relapsing remitting is the most common type of multiple sclerosis, affecting approximately 85% of all patients. Previous evidence has suggested that the risk factors for developing relapsing remitting multiple sclerosis is multifactorial.
James Hill
exaly +2 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Therapeutic inertia in relapsing-remitting multiple sclerosis
Multiple Sclerosis and Related Disorders, 2021Therapeutic inertia (TI) is defined as a failure to initiate or intensify treatments despite evidence of disease activity. Its prevalence and determining factors in Relapsing-Remitting Multiple Sclerosis (RRMS) patients in Portugal are not known. The main objective of this work was to ascertain the prevalence of TI in RRMS and its determining factors ...
Rita, Rodrigues +12 more
openaire +2 more sources
Daclizumab for relapsing remitting multiple sclerosis
Cochrane Database of Systematic Reviews, 2012The anti-CD25 treatment of daclizumab appears to be effective in patients with relapsing remitting multiple sclerosis (RRMS) as regards clinical and MRI outcomes. Moreover, there are no severe safety concerns arising from clinical testing so far.To assess the efficacy and safety of daclizumab for the clinical progression of patients with relapsing ...
Jia, Liu +3 more
openaire +3 more sources
Fingolimod for relapsing-remitting multiple sclerosis
Cochrane Database of Systematic Reviews, 2016Fingolimod was approved in 2010 for the treatment of patients with the relapsing-remitting (RR) form of multiple sclerosis (MS). It was designed to reduce the frequency of exacerbations and to delay disability worsening. Issues on its safety and efficacy, mainly as compared to other disease modifying drugs (DMDs), have been raised.To assess the safety ...
Loredana, La Mantia +5 more
openaire +2 more sources
Lancet, The, 2012 Background The anti-CD52 monoclonal antibody alemtuzumab reduced disease activity in a phase 2 trial of previously untreated patients with relapsing-remitting multiple sclerosis.
Jeffrey A Cohen +2 more
exaly +2 more sources
Relapsing-remitting tumefactive multiple sclerosis
Multiple Sclerosis Journal, 2005Tumefactive multiple sclerosis (MS) is a rare form of demyelinating disease. The natural course of the disease has been characterized as presenting with a mass-like demyelinating lesion converting to typical relapsing-remitting disease with future exacerbations.
Stephen M, Selkirk, Jiong, Shi
openaire +2 more sources
Cyclophosphamide in relapsing remitting multiple sclerosis
The Italian Journal of Neurological Sciences, 19907 patients with relapsing-remitting multiple sclerosis (MS) were subjected to an intensive course of intravenous (I.V.) cyclophosphamide (CY) therapy. All patients received induction therapy with 11 daily doses of 300 mg/m2 and then a single dose every six months for three years.
F, D'Andrea +3 more
openaire +2 more sources
Rituximab for relapsing-remitting multiple sclerosis
Cochrane Database of Systematic Reviews, 2013This is an update of the Cochrane review "Rituximab for relapsing-remitting multiple sclerosis" (first published in The Cochrane Library 2011, Issue 12).More than 80% of individuals with multiple sclerosis (MS) experience a relapsing-remitting disease course.
Dian, He +5 more
openaire +2 more sources